Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Currently (October 2022) Senior Staff Scientist at the Davenport Lab, Sanger Institute, Cambridge, UK.


Katie_BurnhamMy research involves using a functional genomics approach to explore heterogeneity in inflammatory and infectious disease. I am particularly interested in the role of regulatory variation in disease susceptibility and severity, and how an improved understanding of this may inform clinical decision making and drug discovery.

I obtained my DPhil in Clinical Medicine in the Knight group as part of the Nuffield Department of MedicinePhD programme. My thesis focused on sepsis, which is defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, and is a leading cause of death both in the UK and worldwide. It is a complex and heterogeneous disease, and the factors underlying mortality and morbidity are poorly understood. As part of the UK Genomic Advances in Sepsis (GAinS) study, we were interested in how inter-individual variation in the host response to sepsis related to disease susceptibility and outcome. Subsequent to completing my DPhil, I have continued working on this project, using complementary -omics data sets to explore disease subgroups or endotypes revealed by host transcriptomics that could present an opportunity for a precision medicine approach to sepsis management.

In addition, I am working with a large cohort of Emirati individuals (Abu Dhabi, United Arab Emirates) with a high incidence of Type 2 diabetes. Through analysis of genotyping information from patients and controls, together with RNA sequencing data, we hope to identify population-specific gene regulation and disease risk variants. My role in the project is analysis of the RNA-seq data and mapping of expression quantitative trait loci (eQTL) in this population.